Differentiating drug-induced parkinsonism from Parkinson's disease: An update on non-motor symptoms and investigations

Parkinsonism and Related Disorders

Volumn 20, Issue 8, 2014, Pages 808-814

  Brigo, Francesco ^a,b   Erro, Roberto ^b,c   Marangi, Antonio ^b   Bhatia, Kailash ^c   Tinazzi, Michele ^b  

^a Laboratorio Analisi   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Differential diagnosis; Dopamine transporter imaging; Drug induced parkinsonism; Non motor symptoms; Parkinson's disease; Transcranial sonography of the substantia nigra

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; DOPAMINE TRANSPORTER; IOFLUPANE I 123; LEVODOPA;

ATTENTION DEFICIT DISORDER; COGNITION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; DOPAMINERGIC SYSTEM; DRUG INDUCED DISEASE; DRUG INDUCED PARKINSONISM; FEMALE; HUMAN; HYPOSMIA; IDIOPATHIC DISEASE; MAJOR CLINICAL STUDY; MALE; NON MOTOR SYMPTOM SCALE; PARKINSONISM; PRIORITY JOURNAL; PROGNOSIS; RATING SCALE; REVIEW; SCINTIGRAPHY; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SLEEP DISORDER; SMOKING; SUBSTANTIA NIGRA; SYMPATHETIC INNERVATION; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TRANSCRANIAL DOPPLER; URINARY DYSFUNCTION; CHEMICALLY INDUCED; PARKINSON DISEASE; PARKINSONIAN DISORDERS;

DIAGNOSIS, DIFFERENTIAL; HUMANS; PARKINSON DISEASE; PARKINSONIAN DISORDERS;

EID: 84905253917     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2014.05.011     Document Type: Review

References (38)

1. López-Sendón J., Mena M.A., de Yébenes J.G. Drug-induced parkinsonism. Expert Opin Drug Saf 2013, 12:487-496.
2. Mena M.A., de Yébenes J.G. Drug-induced parkinsonism. Expert Opin Drug Saf 2006, 5:759-771.
3. de la Fuente-Fernández R., Schulzer M., Kuramoto L., Cragg J., Ramachandiran N., Au W.L., et al. Age-specific progression of nigrostriatal dysfunction in Parkinson's disease. Ann Neurol 2011, 69:803-810.
4. Bower J.H., Maraganore D.M., McDonnell S.K., Rocca W.A. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology 1999, 52:1214-1220.
5. Martí-Massó J.F., Poza J.J. Cinnarizine-induced parkinsonism: ten years later. Mov Disord 1998, 13:453-456.
6. Lòpez-Sendon J.L., Mena M.A., de Yèbenes J.G. Drug-induced parkinsonism in the elderly: incidence, management and prevention. Drugs Aging 2012, 29:105-118.
7. Hassin-Baer S., Sirota P., Korczyn A.D., Treves T.A., Epstein B., Shabtai H., et al. Clinical characteristics of neuroleptic-induced parkinsonism. JNeural Transm 2001, 108:1299-1308.
8. Tolosa E., Coelho M., Gallardo M. DAT-imaging in drug-induced and psychogenic parkinsonism. Mov Disord 2003, 18(Suppl.7):S28-S33.
9. Lorberboym M., Treves T.A., Melamed E., Lampl Y., Hellmann M., Djaldetti R. [123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease. Mov Disord 2006, 21:510-514.
10. Erro R., Picillo M., Vitale C., Amboni M., Moccia M., Longo K., et al. Non-motor symptoms in early Parkinson's disease: a 2-year follow-up study on previously untreated patients. JNeurol Neurosurg Psychiatry 2013, 84:14-17.
11. Postuma R.B., Aarsland D., Barone P., Burn D.J., Hawkes C.H., Oertel W., et al. Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease. Mov Disord 2012, 27:617-626.
12. Barone P. Neurotransmission in Parkinson's Disease: beyond dopamine. Eur J Neurol 2010, 17:364-376.
13. 123I-metaiodobenzylguanidine (MIBG) scintigraphy and dopamine transporter (DAT) positron emission tomography (PET) predicts prognosis in drug-induced Parkinsonism (DIP): a 2-year follow-up study. Arch Gerontol Geriatr 2013, 56:124-128.
14. Lee P.H., Yeo S.H., Yong S.W., Yun J.K. Odour identification test and its relation to cardiac 123I-metaiodobenzylguanidine in patients with drug induced parkinsonism. JNeurol Neurosurg Psychiatry 2007, 78:1250-1252.
15. Bovi T., Antonini A., Ottaviani S., Antonioli A., Cecchini M.P., Di Francesco V., et al. The status of olfactory function and the striatal dopaminergic system in drug-induced parkinsonism. JNeurol 2010, 257:1882-1889.
16. Morley J.F., Duda J.E. Use of hyposmia and other non-motor symptoms to distinguish between drug-induced parkinsonism and Parkinson's disease. JParkinson's Dis 2014, 1:169-173.
17. Kruger S., Haehner A., Thiem C., Hummel T. Neuroleptic-induced parkinsonism is associated with olfactory dysfunction. JNeurol 2008, 255:1574-1579.
18. Kim J.H., Kim S.Y., Byun H.J. Subjective cognitive dysfunction associated with drug-induced parkinsonism in schizophrenia. Park Relat Disord 2008, 14:239-242.
19. Kim J.H., Byun H.J. Non-motor cognitive-perceptual dysfunction associated with drug-induced parkinsonism. Hum Psychopharmacol 2009, 24:129-133.
20. Kim Y.D., Kim J.S., Chung S.W., Song I.U., Yang D.W., Hong Y.J., et al. Cognitive dysfunction in drug induced parkinsonism (DIP). Arch Gerontol Geriatr 2011, 53:e222-e226.
21. Gaenslen A., Unmuth B., Godau J., Liepelt I., Di Santo A., Schweitzer K.J., et al. The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study. Lancet Neurol 2008, 7:417-424.
22. Bouwmans A.E., Vlaar A.M., Mess W.H., Kessels A., Weber W.E. Specificity and sensitivity of transcranial sonography of the substantia nigra in the diagnosis of Parkinson's disease: prospective cohort study in 196 patients. BMJ Open 2013, 3. pii: e002613.
23. Olivares Romero J., Arjona Padillo A., Barrero Hernández F.J., Martín González M., Gil Extremera B. Utility of transcranial sonography in the diagnosis of drug-induced parkinsonism: a prospective study. Eur J Neurol 2013 Mar 16, 10.1111/ene.12131.
24. Kägi G., Bhatia K.P., Tolosa E. The role of DAT-SPECT in movement disorders. JNeurol Neurosurg Psychiatry 2010, 81:5-12.
25. Vlaar A.M., de Nijs T., Kessels A.G., Vreeling F.W., Winogrodzka A., Mess W.H., et al. Diagnostic value of 123I-ioflupane and 123I-iodobenzamide SPECT scans in 248 patients with parkinsonian syndromes. Eur Neurol 2008, 59:258-266.
26. Cuberas-Borrós G., Lorenzo-Bosquet C., Aguadé-Bruix S., Hernández-Vara J., Pifarré-Montaner P., Miquel F., et al. Quantitative evaluation of striatal I-123-FP-CIT uptake in essential tremor and parkinsonism. Clin Nucl Med 2011, 36:991-996.
27. Bajaj N., Hauser R.A., Grachev I.D. Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes. JNeurol Neurosurg Psychiatry 2013, 84:1288-1295.
28. Diaz-Corrales F.J., Sanz-Viedma S., Garcia-Solis D., Escobar-Delgado T., Mir P. Clinical features and 123I-FP-CIT SPECT imaging in drug-induced parkinsonism and Parkinson's disease. Eur J Nucl Med Mol Imaging 2010, 37:556-564.
29. Lorberboym M., Treves T.A., Melamed E., Lampl Y., Hellmann M., Djaldetti R. [123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease. Mov Disord 2006, 21:510-514.
30. Olivares Romero J., Ariona Padillo A. Diagnostic accuracy of 123 I-FP-CIT SPECT in diagnosing drug-induced parkinsonism: a prospective study. Neurologia 2013, 28:276-282.
31. Tinazzi M., Ottaviani S., Isaias I.U., Pasquin I., Steinmayr M., Vampini C., et al. [123I]FP-CIT SPET imaging in drug-induced Parkinsonism. Mov Disord 2008, 23:1825-1829.
32. Tinazzi M., Antonini A., Bovi T., Pasquin I., Steinmayr M., Moretto G., et al. Clinical and [123I]FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism. JNeurol 2009, 256:910-915.
33. 123I]FP-CIT single photon emission computed tomography findings in drug-induced Parkinsonism. Schizophr Res 2012, 139:40-45.
34. Tinazzi M., Morgante F., Matinella A., Bovi T., Cannas A., Solla P., et al. Imaging of the dopamine transporter predicts pattern of disease progression and response to levodopa in patients with schizophrenia and parkinsonism: a 2-year follow-up multicenter study. Schizophr Res 2014, 152:344-349.
35. Goldstein D.S. Dysautonomia in Parkinson's disease: neurocardiological abnormalities. Lancet Neurol 2003, 2:669-676.
36. Rascol O., Schelosky L. 123I-metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders. Mov Disord 2009, 24(Suppl.2):S732-S741.
37. Lee P.H., Kim J.S., Shin D.H., Yoon S.N., Huh K. Cardiac 123I-MIBG scintigraphy in patients with drug induced parkinsonism. JNeuro Neurosurg Psychiatry 2006, 77:372-374.
38. Goldstein D.S., Sharabi Y., Karp B.I., Bentho O., Saleem A., Pacak K., et al. Cardiac sympathetic denervation preceding motor signs in Parkinson disease. Clin Aut Res 2007, 17:118-121.